Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics – Pipeline Analysis 2018

Atypical hemolytic uremic syndrome (aHUS), also known as non-diarrhea – associated hemolytic uremic syndrome, is a rare disease characterized by hemolytic anemia, thrombocytopenia, acute kidney failure and uremia.

The signs and symptoms of aHUS include formation of tiny blood clots in various small blood vessels of the body. These clots reduce or prevent proper blood flow to various organs of the body, especially the kidneys. aHUS is a complex disorder; and certain genetic, environmental and immunologic factors plays significant role in its development.

Download the Clinical Trials & Results of Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics at: https://www.pharmaproff.com/request-sample/1036

Company lile ChemoCentryx Inc. is in the process of developing avacopan, an orally-administered drug candidate, that inhibits the complement C5a receptor for the treatment of aHUS. Omeros Corporation, Greenovation Biotech GmbH, and Laboratoris Sanifit S.L. are some other companies developing therapeutic agents for aHUS.

Choroidal Neovascularization Therapeutics Pipeline Analysis 2018

Choroidal neovascularization is a type of medical condition in which new blood vessels are formed from choroid and extend into the subretinal space, or subretinal pigment epithelium, or a combination of both.

The disease can be symptomatized by a painless loss of vision, paracentral or central scotoma, and metamorphopsia. Choroidal neovascularization can be diagnosed by indocyanine green angiography, spectral domain optical coherence tomography, and fluorescein angiography.

People having choroidal neovascularization suffers from loss of vision due to the accumulation of subretinal fluid. Choroidal neovascularization can be treated by angiogenesis inhibitors or anti-VEGF (vascular endothelial growth factors) drugs.

Promedior Inc. is in the process of developing PRM-151 as a cell differentiation modulator for the treatment of choroidal neovascularization. Similarly, Graybug Vision Inc. is also developing GB-102 as a platelet-derived growth factor inhibitor for the treatment of this medical condition. Ohr Pharmaceutical Inc., and Ocugen Inc. are some other key players involved in the treatment of choroidal neovascularization.

For more information about Choroidal Neovascularization Therapeutics Pipeline Analysis request to get the sample report at: https://www.pharmaproff.com/request-sample/1122

Cell Cycle Inhibitors Therapeutics Pipeline Analysis

Cell cycle inhibitors include cyclin inhibitors and cyclin-dependent kinases (CDKs), which plays major role in developing new class of anti-cancer therapies. Also, cell cycle inhibitors in combination with chemotherapy, overcome drug resistance and improve cytotoxic efficacy. CDKs are rational targets for cancer treatment, that could restore cell-cycle checkpoints and may induce apoptosis.

For more information about Cell Cycle Inhibitors Therapeutics Pipeline Request to get a sample report at: https://www.pharmaproff.com/request-sample/1177

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic disorders, developing alvocidib – a potent CDK9 inhibitor in combination with cytarabine and daunorubicin. In April 2018, the company presented preclinical data supporting the apoptosis-inducing activity of alvocidib at the American Association for Cancer Research (AACR) Annual Meeting in the U.S., Chicago.

Boehringer Ingelheim International GmbH is in the process of developing volasertib, a cell-cycle kinase inhibitor by acting as a polo-like kinase 1 (PLK1) antagonist for the treatment of AML. ImmunoGen Inc., Pharma Mar S.A., and Eli Lilly and Company are some other major companies involved in the development of cell cycle inhibitor therapeutics for the management of several diseases.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Adrenocortical Carcinoma Therapeutics – Pipeline Analysis 2018

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney.

Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla). Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome.

Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma.

Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.

For more information about Adrenocortical Carcinoma Therapeutics pipeline analysis request to get a sample report at: https://www.pharmaproff.com/request-sample/1109